奥西卓司他在肾上腺性库欣综合征中的国际真实世界研究
该国际真实世界研究纳入28例肾上腺性库欣综合征患者,其中16例肾上腺皮质癌、12例良性疾病。治疗超过4周者66.7%为应答者,超过12周者应答率升至87.5%,且收缩压和体重显著下降。
要点
- 奥西卓司他治疗肾上腺性库欣综合征超过4周应答率66.7%,超过12周达87.5%。
核心结论
- 奥西卓司他可控制66.7%治疗超过4周的肾上腺性库欣综合征患者的高皮质醇血症,治疗超过12周时应答率达87.5%,并对血压和体重有积极影响。
研究设计与样本
- 国际真实世界研究,纳入28例肾上腺性库欣综合征患者,其中16例肾上腺皮质癌、12例良性疾病。
- 所有接受奥西卓司他治疗者纳入安全性评估,治疗超过4周者(n=21)纳入疗效评估。
主要发现
- 治疗超过4周的患者中66.7%为应答者(28.6%完全应答,38.1%部分应答),治疗超过12周者应答率升至87.5%。
- 9例患者发生一个或多个不良事件,其中56%(n=5)导致奥西卓司他停药。
关键数值与推荐
- 应答定义为尿游离皮质醇(UFC)下降>50%;完全应答为UFC低于正常上限(ULN),部分应答为下降>50%但未恢复正常。
临床怎么用
- 奥西卓司他可用于肾上腺性库欣综合征的高皮质醇血症控制,尤其在其他类固醇合成抑制剂治疗后使用应答概率更高。
- 治疗中需监测不良事件,部分患者可能因不良事件停药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Most of the patients included in the clinical trials and real-world studies with osilodrostat only include patients with adrenocorticotropic hormone dependent Cushing syndrome (CS), while data on the efficacy and safety of osilodrostat in patients with adrenal CS is scarce. OBJECTIVE: To assess the efficacy and safety of osilodrostat in adrenal CS. METHODS: International study of patients with adrenal CS: patients treated with osilodrostat at any time were enrolled in the safety evaluation and those treated for longer than 4 weeks, in the efficacy evaluation. Patients were classified as responders if they experienced a reduction in urinary free cortisol (UFC) >50% (complete responders when UFC levels were below the upper limit of normal [ULN] and partial responders if there was a reduction >50% but not normalization). RESULTS: Twenty-eight patients with adrenal CS were enrolled: 16 with adrenocortical carcinoma and 12 with benign disease. Osilodrostat was used in monotherapy in 22 patients and in combination with metyrapone in 6 cases. In those patients treated for longer than 4 weeks (n = 21), 66.7% were classified as responders (28.6% with complete response and 38.1% with partial response), and for those treated for longer than 12 weeks, the rate of response increased to 87.5% The use of osilodrostat as a nonfirst-line therapy (odds ratio 15.0, P = .010) was a predictor of response. Osilodrostat led to a significant decrease in systolic blood pressure and body weight (P < .05). Nine patients developed one or more adverse events and in 56% (n = 5) led to osilodrostat discontinuation. CONCLUSION: Osilodrostat controls hypercortisolism in 66.7% of patients with adrenal CS treated for longer than 4 weeks and in 87.5% of cases treated for longer than 12 weeks, with a positive impact on blood pressure and body weight. Patients who received osilodrostat after other previous steroidogenesis inhibitors have a higher probability of response.
引用
- Araujo-Castro M, Bancos I, Detomas M, et al. International real-world study on osilodrostat efficacy and safety in adrenal Cushing syndrome. J Clin Endocrinol Metab. 2026. PMID: 41824768. doi:10.1210/clinem/dgag115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。